Benitec reports positive Phase 1b/2a BB-301 data; three OPMD subjects show durable swallowing improvements

Benitec Biopharma Inc.

Subject 1: 41% reduction in total dysphagic symptom burden (SSQ) 12-months post-treatment; VFSS improvements across consistencies.
Subject 2: 91% reduction in SSQ to 68 units (clinically normal) at 12 months; pathologic sequential swallows dropped from 80% to 17%.
Subject 3: 68% reduction in SSQ to 70 units (clinically normal) at 3 months; zero pathologic sequential swallows observed.
No severe adverse events reported; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.